Dr. Yaning Wang is the CEO of Createrna Science & Technology. He was the Director of the Division of Pharmacometrics in the Office of Clinical Pharmacology at FDA until September 2021 and oversaw reviews, research projects, and policy development within the Division of Pharmacometrics for all disease areas. During his service at FDA, Dr. Wang participated in decision-making of several new drug approval for major diseases and drafting various guidelines and regulations, and received numerous awards, including Award of Merit (highest award at FDA) and FDA Outstanding Service Award. Before joining FDA, Dr. Wang received his Ph.D. in Pharmaceutics and master’s degree in Statistics from the University of Florida in 2003. He also obtained a master’s degree in Biochemistry (1999) from National Doping Control Center and a bachelor’s degree in Pharmacy (1996) from Peking University in China. Dr. Wang served as a committee member for multiple Ph.D. candidates from various universities. He mentored more than 70 former research fellows (visiting scholars, post-doctoral scholars, and Ph.D. candidates) at FDA. Dr. Wang is a regulatory expert lecturer for three new drug development and regulatory courses (American Course on Drug Development and Regulatory Sciences, European Course in Pharmaceutical Medicine, Chinese Course on Drug Development and Regulatory Sciences). He served as a board member of the International Society of Pharmacometrics (ISoP) and is a fellow of ISoP. He is a member of the Advisory Committee for Chinese Pharmacometrics Society and a member of the Editorial Advisory Board for the Journal of Pharmacokinetics and Pharmacodynamics. Dr. Wang is an Adjunct Professor in the Department of Pharmaceutics at the University of Florida and Clinical Research Institute at Beijing University. Dr. Wang has published over 120 papers and given over 340 presentations at various national and international meetings as an expert in new drug development and regulation.